- Home
- MRM vs RNAZ Comparison
MRM vs RNAZ Comparison
Compare MRM & RNAZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MRM
- RNAZ
- Stock Information
- Founded
- MRM 2000
- RNAZ 2016
- Country
- MRM Japan
- RNAZ United States
- Employees
- MRM N/A
- RNAZ N/A
- Industry
- MRM Other Consumer Services
- RNAZ Biotechnology: Pharmaceutical Preparations
- Sector
- MRM Consumer Discretionary
- RNAZ Health Care
- Exchange
- MRM Nasdaq
- RNAZ Nasdaq
- Market Cap
- MRM 5.9M
- RNAZ 6.1M
- IPO Year
- MRM 2020
- RNAZ 2021
- Fundamental
- Price
- MRM $1.45
- RNAZ $7.70
- Analyst Decision
- MRM
- RNAZ Strong Buy
- Analyst Count
- MRM 0
- RNAZ 1
- Target Price
- MRM N/A
- RNAZ $280.00
- AVG Volume (30 Days)
- MRM 36.9K
- RNAZ 28.9K
- Earning Date
- MRM 05-20-2025
- RNAZ 08-13-2025
- Dividend Yield
- MRM N/A
- RNAZ N/A
- EPS Growth
- MRM 27.65
- RNAZ N/A
- EPS
- MRM 0.18
- RNAZ N/A
- Revenue
- MRM $52,786,758.00
- RNAZ N/A
- Revenue This Year
- MRM N/A
- RNAZ N/A
- Revenue Next Year
- MRM N/A
- RNAZ N/A
- P/E Ratio
- MRM $7.83
- RNAZ N/A
- Revenue Growth
- MRM 21.55
- RNAZ N/A
- 52 Week Low
- MRM $0.34
- RNAZ $6.15
- 52 Week High
- MRM $8.39
- RNAZ $924.00
- Technical
- Relative Strength Index (RSI)
- MRM 50.91
- RNAZ 44.89
- Support Level
- MRM $1.33
- RNAZ $7.50
- Resistance Level
- MRM $1.50
- RNAZ $8.48
- Average True Range (ATR)
- MRM 0.09
- RNAZ 0.60
- MACD
- MRM -0.04
- RNAZ 0.34
- Stochastic Oscillator
- MRM 24.32
- RNAZ 54.91
About MRM MEDIROM Healthcare Technologies Inc.
MEDIROM Healthcare Technologies Inc provides health services. The company is a franchiser and operator of healthcare salons and operates in segments namely Relaxation Salon, Digital Preventative Healthcare, and Luxury Beauty Segment. The company generates a majority of its revenue from the Relaxation Salon business segment. Geographically, the company generates a maximum share of its revenue from Japan.
About RNAZ TransCode Therapeutics Inc.
TransCode Therapeutics Inc is a biopharmaceutical company focused on developing and commercializing innovative drugs and diagnostics for treating and identifying cancer. TransCode recently commenced its first clinical trial. The Company's lead therapeutic candidate, TTX-MC138, comprises an oligonucleotide conjugated to an iron oxide nanoparticle designed to be administered by infusion to inhibit the ability of metastatic tumor cells to survive. The goal of the therapy, if approved, is to achieve durable disease regression and long-term patient survival.